38 filings
8-K
IKT
Inhibikase Therapeutics Inc
18 Apr 24
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
9:46pm
8-K/A
IKT
Inhibikase Therapeutics Inc
2 Apr 24
Departure of Directors or Certain Officers
5:12pm
8-K
IKT
Inhibikase Therapeutics Inc
7 Feb 24
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7:59am
8-K
IKT
Inhibikase Therapeutics Inc
1 Feb 24
Entry into a Material Definitive Agreement
4:09pm
8-K
IKT
Inhibikase Therapeutics Inc
16 Jan 24
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
4:31pm
8-K
fl96f
20 Sep 23
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
11:23am
8-K
1m0vt uwx80lrg4pp9
17 Jul 23
Other Events
5:29pm
8-K
5po2mbaa cai
29 Jun 23
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
12:15pm
8-K
4rdxmd
28 Jun 23
Submission of Matters to a Vote of Security Holders
7:08am
8-K
n6o7qk
22 Mar 23
Regulation FD Disclosure
4:04pm
8-K
s5m8r9qlfqy19j
13 Mar 23
Other Events
5:26pm
8-K
3cls5bcq sk05
6 Mar 23
Departure of Directors or Certain Officers
4:55pm
8-K
c2yxq ut7en8u7ez0
26 Jan 23
Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering
4:02pm
8-K
hf0uq4 2se7
25 Jan 23
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson’s Disease
9:00am
8-K
izfz1h
24 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:27pm
8-K
uealy
17 Nov 22
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
4:30pm
8-K
bptow6dges1hemcl
7 Nov 22
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
4:01pm
8-K
s6tnmv5
16 Sep 22
Regulation FD Disclosure
4:09pm
8-K
rnppc4 7g8vgpi5
1 Sep 22
Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors
5:30pm
8-K
y3b2wq
15 Aug 22
Regulation FD Disclosure
5:12pm